Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2016’, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Muscle Invasive Bladder Cancer (MIBC)

The report reviews pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Muscle Invasive Bladder Cancer (MIBC) therapeutics and enlists all their major and minor projects

The report assesses Muscle Invasive Bladder Cancer (MIBC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Muscle Invasive Bladder Cancer (MIBC)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Muscle Invasive Bladder Cancer (MIBC) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Argos Therapeutics Inc

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Cold Genesys Inc

F. Hoffmann-La Roche Ltd

MedImmune LLC

Oncolytics Biotech Inc

Sillajen Biotherapeutics

Taris Biomedical LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Muscle Invasive Bladder Cancer (MIBC) Overview 7

Therapeutics Development 8

Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Overview 8

Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis 9

Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Development by Companies 10

Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Investigation by Universities/Institutes 11

Muscle Invasive Bladder Cancer (MIBC) - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Muscle Invasive Bladder Cancer (MIBC) - Products under Development by Companies 15

Muscle Invasive Bladder Cancer (MIBC) - Products under Investigation by Universities/Institutes 16

Muscle Invasive Bladder Cancer (MIBC) - Companies Involved in Therapeutics Development 17

Argos Therapeutics Inc 17

Astellas Pharma Inc 18

Astex Pharmaceuticals Inc 19

AstraZeneca Plc 20

Cold Genesys Inc 21

F. Hoffmann-La Roche Ltd 22

MedImmune LLC 23

Oncolytics Biotech Inc 24

Sillajen Biotherapeutics 25

Taris Biomedical LLC 26

Muscle Invasive Bladder Cancer (MIBC) - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

atezolizumab - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

AZD-1775 + durvalumab - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

AZD-4547 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Cellular Immunotherapy for Oncology - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

CG-0070IT - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

durvalumab - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

erlotinib hydrochloride - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

gemcitabine hydrochloride - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

guadecitabine - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

MTG-202 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

pelareorep - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

pexastimogene devacirepvec - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

rocapuldencel-T - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects 104

Muscle Invasive Bladder Cancer (MIBC) - Product Development Milestones 105

Featured News & Press Releases 105

Jul 13, 2016: TARIS Biomedical Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS) in Patients with Muscle-Invasive Bladder Cancer 105

Jun 08, 2015: Oncolytics Biotech Provides Update at AGM on Planned Registration Program for REOLYSIN 105

Appendix 107

Methodology 107

Coverage 107

Secondary Research 107

Primary Research 107

Expert Panel Validation 107

Contact Us 107

Disclaimer 108

List of Tables

List of Tables

Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016 8

Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by Argos Therapeutics Inc, H2 2016 17

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by Astellas Pharma Inc, H2 2016 18

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by Astex Pharmaceuticals Inc, H2 2016 19

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by AstraZeneca Plc, H2 2016 20

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by Cold Genesys Inc, H2 2016 21

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 22

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by MedImmune LLC, H2 2016 23

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by Oncolytics Biotech Inc, H2 2016 24

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by Sillajen Biotherapeutics, H2 2016 25

Muscle Invasive Bladder Cancer (MIBC) – Pipeline by Taris Biomedical LLC, H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Assessment by Combination Products, H2 2016 28

Number of Products by Stage and Target, H2 2016 30

Number of Products by Stage and Mechanism of Action, H2 2016 32

Number of Products by Stage and Route of Administration, H2 2016 34

Number of Products by Stage and Molecule Type, H2 2016 36

Muscle Invasive Bladder Cancer (MIBC) – Dormant Projects, H2 2016 104

List of Figures

List of Figures

Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016 8

Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Top 10 Targets, H2 2016 29

Number of Products by Stage and Top 10 Targets, H2 2016 29

Number of Products by Top 10 Mechanism of Actions, H2 2016 31

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 31

Number of Products by Routes of Administration, H2 2016 33

Number of Products by Stage and Routes of Administration, H2 2016 33

Number of Products by Molecule Types, H2 2016 35

Number of Products by Stage and Molecule Types, H2 2016 35

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports